Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
20.79
+0.30 (+1.44%)
Streaming Delayed Price
Updated: 2:46 PM EDT, May 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
September 16, 2023
Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule...
Via
Talk Markets
4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 16, 2023
A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
2 Top Biotech Stocks Defying the Bear Market
September 15, 2023
The best may be yet to come for these companies.
Via
The Motley Fool
The Latest Analyst Ratings for Exelixis
September 13, 2023
Via
Benzinga
The Top Healthcare Stocks to Buy With $100
August 30, 2023
Both stocks have outperformed the broader market in the last 12 months.
Via
The Motley Fool
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
August 24, 2023
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...
Via
Benzinga
Where Exelixis Stands With Analysts
August 22, 2023
Via
Benzinga
Analyst Expectations for Exelixis's Future
August 02, 2023
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
August 24, 2023
These two companies make a compelling case for a high price.
Via
The Motley Fool
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
August 21, 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time.
Via
InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
Exelixis Stock Sees Rising Relative Strength Rating
August 14, 2023
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.
Via
Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
August 08, 2023
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
August 08, 2023
Via
Benzinga
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
August 02, 2023
EXEL earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
July 29, 2023
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today.
Via
InvestorPlace
2 Biotech Growth Stocks I'd Buy Right Now
July 27, 2023
Both drugmakers seem to have a bright future ahead.
Via
The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
July 20, 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector.
Via
InvestorPlace
3 No-Brainer Stocks to Buy With $200 Right Now
June 21, 2023
A modest amount of money can go a long way when it's invested in game-changing businesses.
Via
The Motley Fool
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
May 29, 2023
These companies can take investors on a lucrative ride, and all for the price of a few lattes.
Via
The Motley Fool
8 Analysts Have This to Say About Exelixis
May 10, 2023
Via
Benzinga
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
May 10, 2023
EXEL earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Exelixis: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
What 9 Analyst Ratings Have To Say About Exelixis
April 12, 2023
Via
Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
May 24, 2023
Companies that don't make a lot of noise can still make you a lot of money.
Via
The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
May 20, 2023
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines.
Via
The Motley Fool
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip
May 13, 2023
A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals.
Via
The Motley Fool
Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns
May 08, 2023
Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board,
Via
Benzinga
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
April 22, 2023
These cheap stocks have the potential to skyrocket over the long haul.
Via
The Motley Fool
Nasdaq Bear Market: 5 Sensational Growth Stocks You'll Regret Not Buying on the Dip
April 22, 2023
Opportunistic investors would be wise to pounce on innovative growth stocks following a 33% decline in the Nasdaq Composite.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.